Logo image of 1BSX.MI

BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Fundamental Analysis

Europe - BIT:1BSX - US1011371077 - Common Stock

85.8 EUR
+2.8 (+3.37%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 1BSX. 1BSX was compared to 62 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of 1BSX get a neutral evaluation. Nothing too spectacular is happening here. 1BSX is valued quite expensively, but it does show have an excellent growth rating. This makes 1BSX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

1BSX had positive earnings in the past year.
In the past year 1BSX had a positive cash flow from operations.
1BSX had positive earnings in 4 of the past 5 years.
1BSX had a positive operating cash flow in each of the past 5 years.
1BSX.MI Yearly Net Income VS EBIT VS OCF VS FCF1BSX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

1BSX has a Return On Assets of 6.03%. This is in the better half of the industry: 1BSX outperforms 69.84% of its industry peers.
1BSX's Return On Equity of 11.17% is fine compared to the rest of the industry. 1BSX outperforms 69.84% of its industry peers.
1BSX's Return On Invested Capital of 7.66% is fine compared to the rest of the industry. 1BSX outperforms 66.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1BSX is below the industry average of 8.76%.
The 3 year average ROIC (6.54%) for 1BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROIC 7.66%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1BSX.MI Yearly ROA, ROE, ROIC1BSX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

The Profit Margin of 1BSX (13.54%) is better than 79.37% of its industry peers.
1BSX's Profit Margin has declined in the last couple of years.
1BSX has a Operating Margin of 18.69%. This is amongst the best in the industry. 1BSX outperforms 80.95% of its industry peers.
1BSX's Operating Margin has been stable in the last couple of years.
1BSX's Gross Margin of 68.30% is fine compared to the rest of the industry. 1BSX outperforms 77.78% of its industry peers.
In the last couple of years the Gross Margin of 1BSX has remained more or less at the same level.
Industry RankSector Rank
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
1BSX.MI Yearly Profit, Operating, Gross Margins1BSX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

5

2. Health

2.1 Basic Checks

1BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
1BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for 1BSX has been increased compared to 5 years ago.
The debt/assets ratio for 1BSX is higher compared to a year ago.
1BSX.MI Yearly Shares Outstanding1BSX.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
1BSX.MI Yearly Total Debt VS Total Assets1BSX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

1BSX has an Altman-Z score of 5.39. This indicates that 1BSX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.39, 1BSX belongs to the top of the industry, outperforming 84.13% of the companies in the same industry.
1BSX has a debt to FCF ratio of 3.33. This is a good value and a sign of high solvency as 1BSX would need 3.33 years to pay back of all of its debts.
The Debt to FCF ratio of 1BSX (3.33) is better than 77.78% of its industry peers.
1BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 1BSX (0.50) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Altman-Z 5.39
ROIC/WACC0.94
WACC8.16%
1BSX.MI Yearly LT Debt VS Equity VS FCF1BSX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

1BSX has a Current Ratio of 1.37. This is a normal value and indicates that 1BSX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, 1BSX perfoms like the industry average, outperforming 47.62% of the companies in the same industry.
1BSX has a Quick Ratio of 1.37. This is a bad value and indicates that 1BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
1BSX has a Quick ratio of 0.82. This is comparable to the rest of the industry: 1BSX outperforms 41.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.82
1BSX.MI Yearly Current Assets VS Current Liabilites1BSX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

8

3. Growth

3.1 Past

1BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.91%, which is quite impressive.
Measured over the past years, 1BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
The Revenue has grown by 21.45% in the past year. This is a very strong growth!
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%

3.2 Future

1BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
Based on estimates for the next years, 1BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.12% on average per year.
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
1BSX.MI Yearly Revenue VS Estimates1BSX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
1BSX.MI Yearly EPS VS Estimates1BSX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 35.45, 1BSX can be considered very expensive at the moment.
1BSX's Price/Earnings ratio is in line with the industry average.
1BSX is valuated rather expensively when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 29.20, the valuation of 1BSX can be described as expensive.
1BSX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.99. 1BSX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 35.45
Fwd PE 29.2
1BSX.MI Price Earnings VS Forward Price Earnings1BSX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

1BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 1BSX is more expensive than 61.90% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1BSX is valued a bit cheaper than the industry average as 68.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 42.63
EV/EBITDA 32.2
1BSX.MI Per share data1BSX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

1BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
1BSX has a very decent profitability rating, which may justify a higher PE ratio.
1BSX's earnings are expected to grow with 15.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.77
PEG (5Y)3.71
EPS Next 2Y16.93%
EPS Next 3Y15.51%

0

5. Dividend

5.1 Amount

1BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BOSTON SCIENTIFIC CORP

BIT:1BSX (10/20/2025, 7:00:00 PM)

85.8

+2.8 (+3.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-23 2025-07-23/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap127.13B
Revenue(TTM)18.49B
Net Income(TTM)2.50B
Analysts86.34
Price Target108.53 (26.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)1.38%
PT rev (3m)2.32%
EPS NQ rev (1m)-0.04%
EPS NQ rev (3m)2.33%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)2.02%
Valuation
Industry RankSector Rank
PE 35.45
Fwd PE 29.2
P/S 8.03
P/FCF 42.63
P/OCF 34.67
P/B 6.62
P/tB N/A
EV/EBITDA 32.2
EPS(TTM)2.42
EY2.82%
EPS(NY)2.94
Fwd EY3.42%
FCF(TTM)2.01
FCFY2.35%
OCF(TTM)2.48
OCFY2.88%
SpS10.69
BVpS12.95
TBVpS-1.69
PEG (NY)1.77
PEG (5Y)3.71
Graham Number26.56
Profitability
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROCE 9.51%
ROIC 7.66%
ROICexc 7.77%
ROICexgc 26.52%
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
FCFM 18.84%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Debt/EBITDA 2.33
Cap/Depr 60.84%
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion 89.77%
Profit Quality 139.08%
Current Ratio 1.37
Quick Ratio 0.82
Altman-Z 5.39
F-Score5
WACC8.16%
ROIC/WACC0.94
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI.


What is the valuation status of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (1BSX.MI). This can be considered as Overvalued.


What is the profitability of 1BSX stock?

BOSTON SCIENTIFIC CORP (1BSX.MI) has a profitability rating of 6 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (1BSX.MI) is 35.45 and the Price/Book (PB) ratio is 6.62.


Can you provide the financial health for 1BSX stock?

The financial health rating of BOSTON SCIENTIFIC CORP (1BSX.MI) is 5 / 10.